Shao Shi-Qi, Zhang Xin-Yin, Feng Kun, He Yun-Yan, Xiong Xiao-Mi, Hua Zi-Yu
Department of Neonatology, Children's Hospital of Chongqing Medical University/Ministry of Education Key Laboratory of Child Development and Disorders/National Clinical Research Center for Child Health and Disorders/China International Science and Technology Cooperation Base of Child Development and Critical Disorders/Chongqing Key Laboratory of Pediatrics, Chongqing 400014, China.
Zhongguo Dang Dai Er Ke Za Zhi. 2021 Jun;23(6):582-587. doi: 10.7499/j.issn.1008-8830.2101167.
To evaluate the efficacy of sepsis risk calculator (SRC) in guiding antibiotic use in neonates with suspected early-onset sepsis (EOS).
A total of 284 neonates with a gestational age of ≥ 35 weeks were enrolled as the control group, who were hospitalized in the Children's Hospital of Chongqing Medical University from March to July, 2019 and were suspected of EOS. Their clinical data were retrospectively collected and the use of antibiotics was analyzed based on SRC. A total of 170 neonates with a gestational age of ≥ 35 weeks were enrolled as the study group, who were admitted to the hospital from July to November, 2020 and were suspected of EOS. SRC was used prospectively for risk scoring to assist the decision making of clinical antibiotic management. The two groups were compared in terms of the rate of use of antibiotics, blood culture test rate, clinical outcome, and adherence to the use of SRC.
Compared with the control group, the study group had a significantly higher SRC score at birth and on admission ( < 0.05). The rate of use of antibiotics in the study group was significantly lower than that in the control group[84.7% (144/170) vs 91.5% (260/284), 6.8% decrease; < 0.05]. The blood culture test rate in the study group was also significantly lower than that in the control group (85.3% vs 91.9%, < 0.05). There was no significant difference between the two groups in the incidence rate of adverse outcomes and the final diagnosis of EOS ( > 0.05).
The use of SRC reduces the rate of empirical use of antibiotics in neonates with suspected EOS and does not increase the risk of adverse outcomes, and therefore, it holds promise for clinical application.
评估脓毒症风险计算器(SRC)在指导疑似早发型脓毒症(EOS)新生儿使用抗生素方面的疗效。
选取284例胎龄≥35周的新生儿作为对照组,于2019年3月至7月在重庆医科大学附属儿童医院住院,均疑似EOS。回顾性收集其临床资料,并基于SRC分析抗生素使用情况。选取170例胎龄≥35周的新生儿作为研究组,于2020年7月至11月入院,均疑似EOS。前瞻性地使用SRC进行风险评分,以辅助临床抗生素管理决策。比较两组抗生素使用率、血培养检查率、临床结局及SRC使用依从性。
与对照组相比,研究组出生时及入院时SRC评分显著更高(<0.05)。研究组抗生素使用率显著低于对照组[84.7%(144/170)对91.5%(260/284),降低6.8%;<0.05]。研究组血培养检查率也显著低于对照组(85.3%对91.9%,<0.05)。两组不良结局发生率及EOS最终诊断率差异无统计学意义(>0.05)。
使用SRC可降低疑似EOS新生儿经验性使用抗生素的比例,且不增加不良结局风险,因此具有临床应用前景。